A transcatheter functional valve replacement for tricuspid valve insufficiency
Tricuspid regurgitation (TR) is a cardiac disorder in which the tricuspid valve leaks during systole causing blood backflow, resulting in decreased cardiac output. TR is the most common valvular heart disease affecting 65%-85% of...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
TriSol System
A heart valve prosthesis and delivery system intended to rep...
71K€
Cerrado
Trisol System
A safe and effective replacement valve for treating severe T...
3M€
Cerrado
TRICARIX
Minimally invasive transcatheter system for tricuspid heart...
4M€
Cerrado
Duo
Duo A minimally invasive device to treat all patients with...
4M€
Cerrado
CVTVT
A Non Surgical Treatment to Restore Heart Valve Function
5M€
Cerrado
Contraband
ContraBand: the only heart failure medical device that is pl...
4M€
Cerrado
Información proyecto Trillium
Duración del proyecto: 46 meses
Fecha Inicio: 2022-07-08
Fecha Fin: 2026-05-31
Líder del proyecto
INNOVENTRIC LTD
No se ha especificado una descripción o un objeto social para esta compañía.
Presupuesto del proyecto
6M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Tricuspid regurgitation (TR) is a cardiac disorder in which the tricuspid valve leaks during systole causing blood backflow, resulting in decreased cardiac output. TR is the most common valvular heart disease affecting 65%-85% of the global population in its mild form. However, mild TR can progress to severe TR, leading to heart failure or death if left untreated. Today, the only option for treatment is valve repair or replacement through open-heart surgery, which is associated with high mortality rates, risks, and costs. Over 3M patients suffer from TR in Europe, and for the majority, their condition is too severe for surgery; therefore, there is no effective treatment. Innoventric has developed the Trillium™ - a transcatheter tricuspid valve replacement solution: the whole procedure is minimally invasive and can be completed in 30mins. Within the EIC project, Innoventric will finalize the clinical validation of its device, ensuring safe and timely intervention for TR patients.